UCSF researchers designed new drug candidates that potently block MPro, a viral enzyme that's crucial for SARS-CoV-2 replication. One of these drug candidates, AVI-4516, is shown (center) bound to the ...
Over the last few years, the SARS-CoV-2 virus, responsible for COVID-19, has undergone significant changes, evolving from the original wild-type strains to the highly transmissible Omicron variant.
Many proteins have a complex architecture that enables biological functions. Molecules can bind to specific sites on a ...
9don MSN
A potential broad coronavirus drug target: Blocking tRNA-modifying enzymes slows viral proteins
Coronaviruses not only use the machinery of the human cells they infect: they modify them to achieve optimal conditions to ...
The RNA-based Nipah virus, which causes acute respiratory illness and fatal encephalitis, can be transmitted from fruit bats to humans directly or indirectly via pigs or horses. Researchers at Wuhan ...
Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today announced results from a randomized, double-blind, placebo-controlled Phase 1b/2a ...
FDA has approved Phase II trial for IN002.5.1 SARS-CoV-2 mRNA vaccine. This approval paves the way for the development of combined respiratory virus vaccines. We are thrilled with the FDA's approval ...
The COVID-19 pandemic highlighted the urgent need for effective therapeutic agents against SARS-CoV-2. Although vaccines helped control the spread of the virus, the emergence of new variants continues ...
Many proteins have a complex architecture that enables biological functions. Molecules can bind to specific sites on a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results